Development and validation of a new bioanalytical method for quantification of CDK4/6 inhibitor in Spiked Human Plasma by HPLC-UV

1 DiPippo AJ, Patel NK, Barnett CM. Cyclin‐dependent kinase inhibitors for the treatment of breast cancer: past, present, and future. Pharmacotherapy. 2016;36(6):652-67. Search in Google Scholar

2 Cha C, Ahn SG, Yoo TK, Kim KM, Bae SJ, Yoon C, et al. Local treatment in addition to endocrine therapy in hormone receptor-positive and HER2-negative oligometastatic breast cancer patients: a retrospective multicenter analysis. Breast Care. 2020;15(4):408-14. Search in Google Scholar

3 Barroso-Sousa R, Shapiro GI, Tolaney SM. Clinical development of the CDK4/6 inhibitors ribociclib and abemaciclib in breast cancer. Breast Care. 2016;11(3):167-73. Search in Google Scholar

4 Curigliano G, Pardo PG, Meric-Bernstam F, Conte P, Lolkema MP, Beck JT, et al. Ribociclib plus letrozole in early breast cancer: a presurgical, window-of-opportunity study. The Breast. 2016;28:191-8. Search in Google Scholar

5 Geoerger B, Bourdeaut F, DuBois SG, Fischer M, Geller JI, Gottardo NG, et al. A phase I study of the CDK4/6 inhibitor ribociclib (LEE011) in pediatric patients with malignant rhabdoid tumors, neuroblastoma, and other solid tumors. Clin Cancer Res. 2017;23(10): 2433-41. Search in Google Scholar

6 Spring LM, Wander SA, Andre F, Moy B, Turner NC, Bardia A. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. The Lancet. 2020;395(10226):817-27. Search in Google Scholar

7 Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer. 2017;17(2):93-115. Search in Google Scholar

8 Sherr CJ. Cancer cell cycles. Science. 1996;274(5293):1672-7. Search in Google Scholar

9 Suárez-Arroyo IJ, Loperena-Alvarez Y, Rosario-Acevedo R, Martínez-Montemayor MM. Ganoderma spp.: a promising adjuvant treatment for breast cancer. Medicines. 2017;4(1):15. Search in Google Scholar

10 Tripathy D, Bardia A, Sellers WR. Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors Mechanism of Action and Clinical Impact of Ribociclib. Clin Cancer Res. 2017; 23(13):3251-62. Search in Google Scholar

11 Verheijen RB, Yu H, Schellens JH, Beijnen JH, Steeghs N, Huitema AD. Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology. Clin Pharmacol Ther. 2017; 102(5):765-76. Search in Google Scholar

12 van Nuland M, Rosing H, Schellens JH, Beijnen JH. Bioanalytical LC–MS/MS validation of therapeutic drug monitoring assays in oncology. Biomed Chromatogr. 2020;34(1):e4623. Search in Google Scholar

13 Posocco B, Buzzo M, Poetto AS, Orleni M, Gagno S, Zanchetta M, et al. Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application. PloS One. 2020;15(2):e0228822. Search in Google Scholar

14 Bao X, Wu J, Sanai N, Li J. Determination of total and unbound ribociclib in human plasma and brain tumor tissues using liquid chromatography coupled with tandem mass spectrometry. J Pharm Biomed Anal. 2019;166:197-204. Search in Google Scholar

15 Braal CL, Lam MH, Rienks T, van Tilborg CJ, Heuts W, Heijns JB, et al. Quantification of ribociclib in dried blood spots by LC–MS/MS: Method development and clinical validation. J Pharm Biomed Anal. 2021;201:114118. Search in Google Scholar

16 Turković L, Bočkor L, Ekpenyong O, Silovski T, Lovrić M, Crnković S, et al. Development and validation of a novel LC-MS/MS method for the simultaneous determination of Abemaciclib, Palbociclib, Ribociclib, Anastrozole, Letrozole, and Fulvestrant in Plasma Samples: A prerequisite for personalized breast cancer treatment. Pharmaceuticals. 2022;15(5):614. Search in Google Scholar

17 Kamble SN, Munipalli VK, Talapadatur H, Singh RM, Warde S, Nayak S, et al. Development and validation of novel HPLC method for analytical evaluation of Lemborexant in tablet dosage form. GSCARR. 2022;11(1):132-43. Search in Google Scholar

18 Meesters R, Voswinkel S. Bioanalytical method development and validation: from the USFDA 2001 to the USFDA 2018 guidance for industry. J Appl Bioanal. 2018;4 (3):67-73. Search in Google Scholar

19 Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation, Department of Health & Human Services. 2001:4-10. [ http://www.labcompliance.de/documents/FDA/FDA-Others/Laboratory/f-507bioanalytical-4252fnl.pdf]. Search in Google Scholar